Q-omics provides the consensus-scored CACHD1 profile across patient tissues and cancer cell-line models. CACHD1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CACHD1 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, CACHD1 RNA expression shows 19,043 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, LUAD, and THYM as cancer lineages where CACHD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CACHD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CACHD1 survival associations across molecular data types. CACHD1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CACHD1 RNA expression–survival associations across cancer types. High CACHD1 expression shows unfavorable associations in KIRP, ACC and LGG, but favorable associations in MESO, KIRC and UCS. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CACHD1 RNA expression.
This table summarizes CACHD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CACHD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CACHD1 shows lower tumor expression in LUAD, KICH, BRCA, KIRP and LUSC and higher tumor expression in LIHC. The LUAD box plot shows higher CACHD1 RNA expression in normal versus tumor tissue (log2 FC = −2.491, t-test p < 0.001).
This table shows molecular features associated with CACHD1 in patient tissues and cancer cell lines. In patient samples, CACHD1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CACHD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
